El-Mokadem Ismail, Lim Alison, Kidd Thomas, Garret Katherine, Pratt Norman, Batty David, Fleming Stewart, Nabi Ghulam
Academic Section of Urology, Division of Cancer Research, Ninewells Hospital, University of Dundee, Dundee, DD1 9SY, UK.
Department of Pathology, Ninewells Hospital, University of Dundee, Dundee, DD1 9SY, UK.
BMC Cancer. 2016 Jul 27;16:546. doi: 10.1186/s12885-016-2514-8.
Long-term prognostic significance of loss of heterozygosity on chromosome 9p21 for localized renal cell carcinoma following surgery remains unreported. The study assessed the frequency of deletions of different loci of chromosome 9p along with immunohistochemical profile of proteins in surgically resected renal cancer tissue and correlated this with long-term outcomes.
DNA was extracted from renal tumours and corresponding normal kidney tissues in prospectively collected samples of 108 patients who underwent surgical resection for clinically localized disease between January 2001 and December 2005, providing a minimum of 9 years follow-up for each participant. After checking quality of DNA, amplified by PCR, loss of heterozygosity (LOH) on chromosome 9p was assessed using 6 microsatellite markers in 77 clear cell carcinoma. Only 5 of the markers showed LOH (D9S1814, D9S916, D9S974, D9S942, and D9S171). Protein expression of p15(INK4b), p16(INK4a), p14(ARF), CAIX, and adipose related protein (ADFP) were demonstrated by immunostaining in normal and cancer tissues. Loss of heterozygosity for microsatellite analysis was correlated with tumour characteristics, recurrence free, cancer specific, and overall survival, including significance of immunohistochemical profile of protein expressions.
The main deletion was found at loci telomeric to CDKN2A region at D9S916. There was a significant correlation between frequency of LOH stage (p = 0.005) and metastases (p = 0.006) suggesting a higher LOH for advanced and aggressive renal cell carcinoma. Most commonly observed LOH in the 3 markers: D9S916, D9S974, and D9S942 were associated with poor survival, and were statistically significant on multivariate analysis. Immunohistochemical expression of p14, p15, and p16 proteins were either low or absent in cancer tissue compared to normal.
Loss of heterozygosity of p921 chromosome is associated with aggressive tumours, and predicts cancer specific or recurrence free survival on long-term follow-up.
9号染色体短臂21区杂合性缺失对手术切除后的局限性肾细胞癌的长期预后意义尚未见报道。本研究评估了手术切除的肾癌组织中9号染色体短臂不同位点的缺失频率以及蛋白质的免疫组化特征,并将其与长期预后相关联。
从2001年1月至2005年12月期间因临床局限性疾病接受手术切除的108例患者的前瞻性收集样本中的肾肿瘤及相应正常肾组织中提取DNA,为每位参与者提供至少9年的随访。在检查DNA质量后,通过PCR扩增,使用6个微卫星标记在77例透明细胞癌中评估9号染色体短臂的杂合性缺失(LOH)。仅5个标记显示出LOH(D9S1814、D9S916、D9S974、D9S942和D9S171)。通过免疫染色在正常组织和癌组织中显示p15(INK4b)、p16(INK4a)、p14(ARF)、CAIX和脂肪相关蛋白(ADFP)的蛋白表达。微卫星分析的杂合性缺失与肿瘤特征、无复发生存、癌症特异性生存和总生存相关,包括蛋白表达的免疫组化特征意义。
主要缺失位于D9S916处CDKN2A区域的端粒位点。LOH频率与分期(p = 0.005)和转移(p = 0.006)之间存在显著相关性,提示晚期和侵袭性肾细胞癌的LOH更高。在3个标记D9S916、D9S974和D9S942中最常观察到的LOH与不良生存相关,在多变量分析中具有统计学意义。与正常组织相比,癌组织中p14、p15和p16蛋白的免疫组化表达较低或缺失。
9号染色体短臂杂合性缺失与侵袭性肿瘤相关,并在长期随访中预测癌症特异性或无复发生存。